PLoS ONE · 2014 · 43 citations · 29 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyTumor ProgressionAngiogenesisAngiogenesis In CancerBreast Cancer PharmacotherapyAngiogenesis-driven GrowthCancer Cell Proliferation InhibitionGrowth FactorsIntraperitoneal AdministrationTriple-negative Breast Cancer TherapyTumor Growth MonitoringTumor Growth Rate
A selective inhibitor of 20-HETE synthesis, HET0016, has been reported to inhibit angiogenesis. 20-HETE has been known as a second mitogenic messenger of angiogenesis inducing growth factors. HET0016 effects were analyzed on MDA-MB-231 derived breast cancer in mouse and in vitro cell line. MDA-MB-231 tumor cells were implanted in animals' right flank and randomly assigned to early (1 and 2), starting treatments on day 0, or delayed groups (3 and 4) on day 8 after implantation of tumor. Animals received HET0016 (10 mg/kg) treatment via intraperitoneal injection for 5 days/week for either 3 or 4 weeks. Control group received vehicle treatment. Tumor sizes were measured on days 7, 14, 21, and 28 and the animals were euthanized on day 22 and 29. Proteins were extracted from the whole tumor and from cells treated with 10 µM HET0016 for 4 and 24 hrs. Protein array kits of 20 different cytokines/factors were used. ELISA was performed to observe the HIF-1α and MMP-2 protein expression. Other markers were confirmed by IHC. HET0016 significantly inhibited tumor growth in all treatment groups at all-time points compared to control (p<0.05). Tumor growth was completely inhibited on three of ten animals on early treatment group. Treatment groups showed significantly lower expression of pro-angiogenic factors compared to control at 21 days; however, there was no significant difference in HIF-1α expression after treatments. Similar results were found in vitro at 24 hrs of HET0016 treatment. After 28 days, significant increase of angiogenin, angiopoietin-1/2, EGF-R and IGF-1 pro-angiogenic factors were found (p<0.05) compared to control, as well as an higher intensity of all factors were found when compared to that of 21 day's data, suggesting a treatment resistance. HET0016 inhibited tumor growth by reducing expression of different set of pro-angiogenic factors; however, a resistance to treatment seemed to happen after 21 days.
29
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Noel Weidner, Joseph P. Semple, William R. Welch et al. · New England Journal of Medicine · 1991 · 5.7K citations
Medicine, Cancer Biology, Oncology +15
Matrix Metalloproteinases Generate Angiostatin: Effects on Neovascularization
Lynn A. Cornelius, Leslie Nehring, E. A. Harding et al. · The Journal of Immunology · 1998 · 439 citations · Full text
Medicine, Cancer Biology, Oncology +15
Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth
Pirjo Laakkonen, Marika Waltari, Tanja Holopainen et al. · Cancer Research · 2007 · 241 citations
Medicine, Cancer Biology, Oncology +15